Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AbbVie (NY:ABBV)

232.36 +0.07 (+0.03%)
Official Closing Price Updated: 7:00 PM EST, Nov 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AbbVie

< Previous 1 2 3 4 5 6 7 8 9
...
89 90 Next >
News headline image
Discover which S&P500 stocks are making waves on Friday. ↗
Stay informed about the performance of the S&P500 index in the middle of the day on Friday. Uncover the top gainers and losers in today's session for valuable insights. 
Via Chartmill
News headline image
AI: The Pharmaceutical Sector’s New Catalyst for a Healthier Future
The pharmaceutical industry is in the midst of a profound and rapid transformation, driven by the pervasive integration of Artificial Intelligence (AI). What was once a futuristic concept is, by late... 
Via TokenRing AI
Topics Animal Testing Artificial Intelligence Economy
News headline image
Why AbbVie (ABBV) Shares Are Falling Today
Shares of pharmaceutical company AbbVie (NYSE:ABBV) fell 3.9% in the afternoon session after the company reported third-quarter results that were overshadowed by a steep drop in profitability and a... 
Via StockStory
Topics World Trade
News headline image
Nasdaq 100 Rebounds, Amazon Jumps 10% On Strong Earnings: What's Moving Markets Friday? ↗
Tech stocks edged higher Friday, rebounding from Thursday's 1.5% drop in the Nasdaq 100 as upbeat earnings from mega-cap giants kept the rally momentum alive. 
Via Benzinga
News headline image
AbbVie Raises 2025 Outlook Helped By Strong Immunology Growth, Boost Dividend ↗
AbbVie beats Q3 estimates with $15.78 billion revenue, boosts dividend to $1.73, raises earnings outlook on strong drug portfolio growth. 
Via Benzinga
News headline image
AbbVie's Earnings Outlook ↗
 
Via Benzinga
News headline image
Gapping S&P500 stocks in Friday's session ↗
Friday's session is showcasing interesting market movements in the S&P500 index, with notable gap up and gap down stocks. Stay updated with the gapping S&P500 stocks in today's session. 
Via Chartmill
News headline image
AbbVie Q3 2025 Earnings Call Transcript ↗
AbbVie Q3 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings Economy
News headline image
ABBVIE INC (NYSE:ABBV) Reports Mixed Q3 2025 Results with EPS Beat and Revenue Miss ↗
AbbVie's Q3 2025 results show a mixed quarter with adjusted EPS beating estimates, but revenue missed and GAAP profit fell sharply. 
Via Chartmill
News headline image
AbbVie Beats Third-Quarter Forecasts As Immunology Kingpin Grows 47% ↗
AbbVie stock dipped early Friday, though the drug giant easily beat views. 
Via Investor's Business Daily
News headline image
AbbVie’s (NYSE:ABBV) Q3 Sales Beat Estimates
Pharmaceutical company AbbVie (NYSE:ABBV) announced better-than-expected revenue in Q3 CY2025, with sales up 9.1% year on year to $15.78 billion. Its non-GAAP profit of $1.86 per share was 4.2% above... 
Via StockStory
Topics Earnings
News headline image
Eli Lilly Extends Lead In $150B Obesity Drug Race As Novo, Pfizer Clash — Here's How ETFs Stand To Gain ↗
As Eli Lilly, Novo Nordisk, and Pfizer battle for dominance in the obesity-drug market, these ETFs are offering exposure to the GLP-1 gold rush. 
Via Benzinga
Topics ETFs
News headline image
Railway Pension Liquidates All 1.65M CCJ Shares Worth $122.8 Million ↗
Railway Pension Liquidates All 1.65M CCJ Shares Worth $122.8 Million 
Via The Motley Fool
Topics Supply Chain
News headline image
AbbVie (ABBV) Reports Earnings Tomorrow: What To Expect
Pharmaceutical company AbbVie (NYSE:ABBV) will be reporting results this Friday before market open. Here’s what you need to know. 
Via StockStory
Topics Artificial Intelligence
News headline image
Want Decades of Passive Income? Buy This Index Fund and Hold It Forever. ↗
This ETF is one of the easiest ways to generate consistent passive income. 
Via The Motley Fool
Topics ETFs Regulatory Compliance Stocks
News headline image
Billionaire Israel "Izzy" Englander Has Loaded Up on This Dividend King. Should You? ↗
Englander seems to have had several good reasons to aggressively buy shares of this big drugmaker. 
Via The Motley Fool
Topics Intellectual Property
News headline image
1 Unpopular Stock That Deserves a Second Chance and 2 Facing Challenges
When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other... 
Via StockStory
News headline image
Prediction: These Dividend Stocks Could Outperform Growth Stocks in the Next Decade ↗
Between growth and dividends, these companies have plenty to offer. 
Via The Motley Fool
Topics Economy Intellectual Property
News headline image
ONEOK’s 6% Dividend Draws Smart Money Despite a Nearly 30% Drop ↗
ONEOK’s 6% Dividend Draws Smart Money Despite a Nearly 30% Drop 
Via The Motley Fool
Topics Energy Regulatory Compliance
News headline image
Retail Investors' Top Stocks With Earnings This Week: SoFi, Apple, Meta And More ↗
Investors are gearing up for a jam-packed week of earnings featuring several big tech names and retail-trader favorites. 
Via Benzinga
News headline image
Why Some Investors Are Taking Profits on JPMorgan After Its Big Rally ↗
Why Some Investors Are Taking Profits on JPMorgan After Its Big Rally 
Via The Motley Fool
News headline image
AbbVie Draws Growing Institutional Confidence As Investors Seek Steady Growth ↗
AbbVie Draws Growing Institutional Confidence As Investors Seek Steady Growth 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
3 Pharmaceutical Growth Stocks to Buy and Hold for 10 Years ↗
Via MarketBeat
News headline image
Bullish Bet: Investment Manager Makes Strategic Buy of Prologis Stock ↗
Bullish Bet: Investment Manager Makes Strategic Buy of Prologis Stock 
Via The Motley Fool
Topics Economy Regulatory Compliance
News headline image
Blue Owl Capital Stock Trimmed by Investment Manager, According to Recent Filing ↗
Blue Owl Capital Stock Trimmed by Investment Manager, According to Recent Filing 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Investment Manager Doubles Down on Regional Bank Stock, According to Recent Filing ↗
Investment Manager Doubles Down on Regional Bank Stock, According to Recent Filing 
Via The Motley Fool
Topics Credit Cards Regulatory Compliance
News headline image
Motley Fool Co-Founder Tom Gardner: The Quarterly Call ↗
In our second Quarterly Call, Motley Fool CEO and co-founder Tom Gardner talked about the current market and what to do about it. Tom also shared five investment ideas. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
AbbVie: Navigating Challenges and Seizing Opportunities in the Pharma Sector ↗
Could AbbVie be the next big opportunity for investors? Tune in as our experts dissect the company's performance and future potential. 
Via The Motley Fool
News headline image
Nurix Therapeutics (NASDAQ: NRIX) Stock Soars as Pivotal Phase 2 Study for Bexobrutideg Ignites Investor Confidence
San Francisco, CA – October 22, 2025 – Nurix Therapeutics (NASDAQ: NRIX) has captured significant market attention, with its stock experiencing a notable surge following the announcement of the... 
Via MarketMinute
News headline image
Qualcomm, Aptiv, Palo Alto And A Health Care Stock On CNBC's 'Final Trades' ↗
Jason Snipe stays long on AbbVie (ABBV). Guggenheim analyst raises price target. QUALCOMM (QCOM) picked by Jim Lebenthal. Stephanie Link picks Aptiv (APTV). Joe Terranova chooses Palo Alto Networks... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
89 90 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.